Clinical trials: Radical Prostatectomy
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Prostate Cancer
Global Performance Evaluation of the AMS CONTINUUM™ Device
1. To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure. 2.
- Trial name
- NCT01083199
- Testing
- CONTINUUM™
- Where
- 2 sites in Greece, Spain
- Volunteers
- 10 people
- Sponsor
- American Medical Systems
Prostate Cancer
Postoperative Pain Control for Prostatectomy
The researchers propose to investigate a relatively new anesthetic procedure, in order to maximize patient comfort and minimize the use of narcotics after a radical prostatectomy.
- Trial name
- TAP (NCT00913068)
- Testing
- Transverse Abdominal Plan (TAP), standard post op pain control
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- Nova Scotia Health Authority
Prostate Cancer
A Study of Olaparib and Durvalumab in Prostate Cancer
The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.
- Trial name
- NCT03810105
- Testing
- Olaparib, Durvalumab
- Where
- 8 sites in United States
- Volunteers
- 5 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
This study was a prospective analysis in men with localized prostate cancer who had rising Prostate Specific Antigen (PSA) levels after definitive treatment with surgery or radiation.
- Trial name
- IAS (NCT00223665)
- Testing
- Flutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Washington
Prostate Cancer
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00002874
- Testing
- bicalutamide, radiation therapy
- Where
- 240 sites in United States, Canada
- Volunteers
- 840 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
RATIONALE: Specialized radiation therapy that delivers a high-dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00528866
- Testing
- bicalutamide, docetaxel, flutamide
- Where
- 70 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Radiation Therapy Oncology Group
Adenocarcinoma of the Prostate
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
- Trial name
- NCT02523924
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy
Improving Erectile Function and Quality of Life After Prostate Cancer Treatment
This is a research study of erectile dysfunction (ED) in men diagnosed with prostate cancer. 144 patients and partners will participate in the study.
- Conditions
- Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Simple Prostatectomy, Erectile Dysfunction
- Trial name
- NCT01996852
- Testing
- Cognitive-behavioral Meetings, sildenafil citrate, Vacuum Constriction Device
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
In April 2011, the United States Food and Drug Administration (FDA) approved the oral drug abiraterone acetate (Zytiga ®) in combination with prednisone (a steroid) to treat patients with metastatic castration-resistant prostate…
- Trial name
- NCT01751451
- Testing
- Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix
- Where
- 16 sites in United States
- Volunteers
- 124 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
The purpose of this research study is to determine if the combination of chemotherapy and hormone therapy is safe and helpful for patients who plan to have their high-risk prostate cancer surgically removed.
- Trial name
- NCT01250717
- Testing
- Docetaxel, Dexamethasone, Estramustine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Beth Israel Deaconess Medical Center
Prostate Cancer
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
- Trial name
- NCT06604442
- Testing
- flotufolastat (18F), piflufolastat (18F)
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- Blue Earth Diagnostics
Erectile Dysfunction Following Radical Prostatectomy
MED3000 Topical Gel for On-Demand Treatment of Post-Radical Prostatectomy Erectile Dysfunction
The investigators are doing this research to evaluate the efficacy and safety of topical MED3000 therapy in men with persistent erectile dysfunction 1.5 to 4 years following radical prostatectomy surgery.
- Trial name
- NCT05673005
- Testing
- MED3000 topical gel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer Adenocarcinoma in Situ
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to…
- Trial name
- NCT01696877
- Testing
- degarelix acetate, Cyclophosphamide, GVAX
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
RATIONALE: The use of diindolylmethane, a substance found in cruciferous vegetables, may slow the growth of tumor cells. PURPOSE: This phase II trial is studying how well diindolylmethane works in treating patients with stage I…
- Trial name
- NCT00888654
- Testing
- B-Dim, Radical Prosatectomy
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
This is a research study to test an investigational drug (Not FDA approved), Apalutamide given in combination with Leuprolide acetate (FDA approved) in men diagnosed with high-risk prostate cancer who have already selected to…
- Trial name
- NCT02770391
- Testing
- Leuprolide acetate, Apalutamide, Radical prostatectomy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Platelet Rich Plasma During Radical Prostatectomy
Can platelet rich plasma applied to nerve bundles at time of surgery help the nerve bundles heal? Subjects undergoing a Radical Prostatectomy who meet study inclusion/exclusion criteria will be consented to receive an…
- Trial name
- NCT02957149
- Testing
- Autologous Platelet-Rich Plasma, Angel Concentrated Platelet Rich Plasma System
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
There is now substantial evidence that B cells are recruited into prostate cancers by CXCL13 released by the tumor cells. B cells release lymphotoxin which drives malignant cell proliferation through the NFkB pathway.
- Trial name
- NCT01804712
- Testing
- rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Christopher Kane
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center